Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 5/20 | 0.56 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | PI4KA | P42356 | 1/20 | 0.50 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.50 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.50 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | GAK | O14976 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4456679 | 0.98 | FGFR1 (0.54) | FGFR1EGFRPI4KAPI4K2BPI4K2A | |
| SCHEMBL3027720 | 0.86 | PI4KA (0.57) | FGFR1EGFRPI4KAPI4K2BPI4K2A | |
| SCHEMBL3697841 | 0.83 | MKNK2 (0.49) | FGFR1EGFRPI4KAPI4K2BPI4K2A | |
| SCHEMBL467133 | 0.83 | MKNK2 (0.47) | FGFR1EGFRPI4KAPI4K2BPI4K2A | |
| SCHEMBL30677290 | 0.78 | CYP1A2 (0.46) | FGFR1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL4542537 | 0.78 | POLB (0.54) | FGFR1HTTMKNK2CYP1A2ALDH1A1 | |
| SCHEMBL27560848 | 0.78 | CYP1A2 (0.41) | FGFR1MKNK2CYP1A2ALDH1A1CYP2C9 | |
| SCHEMBL1408354 | 0.78 | QPCT (0.47) | MKNK2CYP1A2ALDH1A1CYP2C9CYP3A4 | |
| SCHEMBL793846 | 0.77 | MKNK2 (0.48) | FGFR1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL6944930 | 0.77 | PI4KA (0.55) | FGFR1PI4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4363043-B1 | COMPOSITIONS FOR USE IN METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2026-04-22 | — | — | EP | claimed |
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | NOVOCURE GMBH (CH) | 2026-04-07 | — | — | US | claimed |
| US-20250339680-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2025-11-06 | — | — | US | claimed |
| EP-4363043-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | Novocure GmbH (CH) | 2024-05-08 | — | — | EP | claimed |
| CN-117580614-A | Compositions and methods for increasing sensitivity of cancer cells to alternating electric fields | 诺沃库勒有限责任公司 | 2024-02-20 | — | — | CN | claimed |
| CN-116390760-A | Compositions and methods for increasing sensitivity of cancer cells to alternating electric fields | 诺沃库勒有限责任公司 | 2023-07-04 | — | — | CN | claimed |
| EP-4188380-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | Novocure GmbH (CH) | 2023-06-07 | — | — | EP | claimed |
| WO-2023275649-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2023-01-05 | — | — | WO | claimed |
| US-20230001193-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | BIOPHARMA CREDIT PLC (GB) | 2023-01-05 | — | — | US | claimed |
| US-20220096818-A1 | Compositions And Methods For Increasing Cancer Cell Sensitivity To Alternating Electric Fields | BIOPHARMA CREDIT PLC (GB) | 2022-03-31 | — | — | US | claimed |
| WO-2022029628-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2022-02-10 | — | — | WO | claimed |
| US-20140011809-A1 | DRUG DELIVERY TO THE ANTERIOR AND POSTERIOR SEGMENTS OF THE EYE USING EYE DROPS | REKIK RAOUF (TN) | 2014-01-09 | — | — | US | claimed |
| US-20060172922-A1 | Methods for combating ischemic injury to epithelial organ | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-08-03 | — | — | US | claimed |
| US-4169717-A | METAL PROTEINATE AND GROWTH HORMONE | ASHMEAD H H | 1979-10-02 | — | — | US | claimed |
| EP-4363043-B1 | COMPOSITIONS FOR USE IN METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2026-04-22 | — | — | EP | disclosed |
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | NOVOCURE GMBH (CH) | 2026-04-07 | — | — | US | disclosed |
| US-20250339680-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2025-11-06 | — | — | US | disclosed |
| US-4455162-A | POLAR SOLVENTS, METAL SALTS | BIOCHEMICAL RESEARCH CORPORATION (US) | 1984-06-19 | — | — | US | disclosed |
| EP-0079123-A1 | Benzoquinolizines | JOHN WYETH & BROTHER LIMITED (GB) | 1983-05-18 | — | — | EP | disclosed |
| US-4186184-A | Selective administration of drug with ocular therapeutic system | ALZA CORPORATION (US) | 1980-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | PTK2, GSK3B, MTOR | FGFR1 709/4885EGFR 157/4885PI4KA 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.